within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EC02_Dabrafenib;

model Dabrafenib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.95,
    Cl = 4.166666666666667e-06,
    adminDuration = 600,
    adminMass = 150 / 1000000,
    adminCount = 1,
    Vd = 0.0703,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0125,
    Tlag = 10.200000000000001,
    Vdp = 0.294,
    k12 = 6.11111111111111e-06,
    k21 = 6.11111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dabrafenib</td></tr><tr><td>ATC code:</td><td>L01EC02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>150</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>70.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dabrafenib is an oral targeted anti-cancer drug classified as a BRAF inhibitor. It is used primarily for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation. It is also approved for use in combination with other agents for certain other cancer indications. It is widely used and approved for these purposes in clinical practice as of 2024.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with metastatic melanoma. Data derived from phase I/II trial patients, mixed sex, normal kidney and liver function.</p><h4>References</h4><ol><li><p>Cox, DS, et al., &amp; Orford, K (2015). Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. <i>Clinical pharmacology in drug development</i> 4(4) 287–294. DOI:<a href=\"https://doi.org/10.1002/cpdd.152\">10.1002/cpdd.152</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27136909/\">https://pubmed.ncbi.nlm.nih.gov/27136909</a></p></li><li><p>Janssen, JM, et al., &amp; Huitema, ADR (2020). Evaluation of Extrapolation Methods to Predict Trough Concentrations to Guide Therapeutic Drug Monitoring of Oral Anticancer Drugs. <i>Therapeutic drug monitoring</i> 42(4) 532–539. DOI:<a href=\"https://doi.org/10.1097/FTD.0000000000000767\">10.1097/FTD.0000000000000767</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32384536/\">https://pubmed.ncbi.nlm.nih.gov/32384536</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EC02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dabrafenib;
